JP6475712B2 - サイトカインアンタゴニストの標的化 - Google Patents

サイトカインアンタゴニストの標的化 Download PDF

Info

Publication number
JP6475712B2
JP6475712B2 JP2016526507A JP2016526507A JP6475712B2 JP 6475712 B2 JP6475712 B2 JP 6475712B2 JP 2016526507 A JP2016526507 A JP 2016526507A JP 2016526507 A JP2016526507 A JP 2016526507A JP 6475712 B2 JP6475712 B2 JP 6475712B2
Authority
JP
Japan
Prior art keywords
cells
composition
antagonist
targeting moiety
ifn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016526507A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529232A (ja
JP2016529232A5 (enExample
Inventor
タヴェルニエール，ジャン
ザビュー，レナート
ユゼ，ギーユ
ポール，フランシアン
ボーダット，ヤン
ガルサン，ジェネビーブ
Original Assignee
ヴィブ ブイゼットダブリュー
ヴィブ ブイゼットダブリュー
ユニバーシテイト ヘント
ユニバーシテイト ヘント
ソントル ナショナル ド ラ ルシェルシュ シオンティフィック
ソントル ナショナル ド ラ ルシェルシュ シオンティフィック
ウニベルシテ ドゥ モンペリエ
ウニベルシテ ドゥ モンペリエ
ソントル オスピタリエ レジョナル ウニベルシテール ド モンペリエ
ソントル オスピタリエ レジョナル ウニベルシテール ド モンペリエ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴィブ ブイゼットダブリュー, ヴィブ ブイゼットダブリュー, ユニバーシテイト ヘント, ユニバーシテイト ヘント, ソントル ナショナル ド ラ ルシェルシュ シオンティフィック, ソントル ナショナル ド ラ ルシェルシュ シオンティフィック, ウニベルシテ ドゥ モンペリエ, ウニベルシテ ドゥ モンペリエ, ソントル オスピタリエ レジョナル ウニベルシテール ド モンペリエ, ソントル オスピタリエ レジョナル ウニベルシテール ド モンペリエ filed Critical ヴィブ ブイゼットダブリュー
Publication of JP2016529232A publication Critical patent/JP2016529232A/ja
Publication of JP2016529232A5 publication Critical patent/JP2016529232A5/ja
Application granted granted Critical
Publication of JP6475712B2 publication Critical patent/JP6475712B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2016526507A 2013-07-19 2014-07-01 サイトカインアンタゴニストの標的化 Active JP6475712B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306045 2013-07-19
EP13306045.9 2013-07-19
PCT/EP2014/063976 WO2015007520A1 (en) 2013-07-19 2014-07-01 Targeting of cytokine antagonists

Publications (3)

Publication Number Publication Date
JP2016529232A JP2016529232A (ja) 2016-09-23
JP2016529232A5 JP2016529232A5 (enExample) 2017-08-10
JP6475712B2 true JP6475712B2 (ja) 2019-02-27

Family

ID=48874233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016526507A Active JP6475712B2 (ja) 2013-07-19 2014-07-01 サイトカインアンタゴニストの標的化

Country Status (11)

Country Link
US (5) US9732135B2 (enExample)
EP (1) EP3022230B1 (enExample)
JP (1) JP6475712B2 (enExample)
KR (1) KR102305608B1 (enExample)
CN (1) CN105658669A (enExample)
AU (1) AU2014292355B2 (enExample)
CA (1) CA2918119C (enExample)
IL (1) IL243459B (enExample)
MX (1) MX375426B (enExample)
SG (2) SG11201600165WA (enExample)
WO (1) WO2015007520A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013211059B8 (en) * 2012-01-20 2017-12-21 Centre Hospitalier Regional Universitaire De Montpellier Targeted mutant alpha-helical bundle cytokines
US9732135B2 (en) * 2013-07-19 2017-08-15 Vib Vzw Targeting of human interferon antagonists
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
EP4276114A3 (en) 2016-03-07 2024-02-21 Vib Vzw Cd20 binding single domain antibodies
US20190077871A1 (en) * 2016-03-07 2019-03-14 Vib Vzm Cd20 binding agents and uses thereof
US11236141B2 (en) 2016-05-13 2022-02-01 Orionis Biosciences BV Targeted mutant interferon-beta and uses thereof
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
JP7204643B2 (ja) 2016-10-24 2023-01-16 オリオニス バイオサイエンシズ ビーブイ 標的変異インターフェロン－ガンマおよびその使用
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
MX2019009255A (es) 2017-02-06 2019-11-05 Orionis Biosciences Nv Proteínas quiméricas dirigidas y sus usos.
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
WO2019032661A1 (en) * 2017-08-09 2019-02-14 Orionis Biosciences Inc. CD8 LIAISON AGENTS
JP7423511B2 (ja) 2017-08-09 2024-01-29 オリオンズ バイオサイエンス インコーポレイテッド Ｐｄ－１およびｐｄ－ｌ１結合物質
BR112020002706A2 (pt) 2017-08-09 2020-08-25 Orionis Biosciences Inc. agentes de ligação a clec9a e uso dos mesmos
WO2019148089A1 (en) 2018-01-26 2019-08-01 Orionis Biosciences Inc. Xcr1 binding agents and uses thereof
CN112074267B (zh) 2018-02-05 2024-06-28 奥里尼斯生物科学公司股份有限公司 成纤维细胞结合剂及其用途
US12084497B2 (en) 2018-08-08 2024-09-10 Orionis Biosciences, Inc. SIRP1α targeted chimeric proteins and uses thereof
CA3118892A1 (en) 2018-11-08 2020-05-14 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
CN111499718B (zh) * 2019-01-30 2022-06-14 复旦大学 人α干扰素受体结合相关位点突变体及其用途
JP7773372B2 (ja) 2019-03-28 2025-11-19 オリオニス バイオサイエンシズ，インコーポレイテッド 線維芽細胞活性化タンパク質結合物質およびその使用
JP7689079B2 (ja) 2019-03-28 2025-06-05 オリオニス バイオサイエンシズ，インコーポレイテッド 治療用インターフェロンアルファ１タンパク質
US12351614B2 (en) 2019-03-28 2025-07-08 Orionis Biosciences, Inc. CLEC9A-based chimeric protein complexes
US12544426B2 (en) 2019-06-19 2026-02-10 Orionis Biosciences, Inc. Combination therapy with CD13-targeted chimeric proteins or chimeric protein complexes
AU2020312735A1 (en) 2019-07-18 2021-12-16 Enyo Pharma Method for decreasing adverse-effects of interferon
JP2024511465A (ja) 2021-03-26 2024-03-13 イナート・ファルマ・ソシエテ・アノニム Ｎｋ細胞エンゲージングのためにサイトカインに融合したｎｋｐ４６結合性部位、がん抗原結合性部位を含む多特異性タンパク質
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
MX2023014647A (es) 2021-06-09 2024-01-31 Innate Pharma Proteinas de union a nkp46 multiespecificas.
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
WO2024040247A1 (en) 2022-08-18 2024-02-22 Regeneron Pharmaceuticals, Inc. Interferon proproteins and uses thereof
US20240376229A1 (en) 2023-05-12 2024-11-14 Regeneron Pharmaceuticals, Inc. Interferon receptor antagonists and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3115318B2 (ja) 1989-08-22 2000-12-04 イミュネックス・コーポレーション Ｇｍ―ｃｓｆ及びｉｌ―３を含む融合タンパク質
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
US6001973A (en) * 1996-04-26 1999-12-14 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
BR0013231A (pt) * 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
US20020193569A1 (en) 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
JP5208733B2 (ja) 2005-06-29 2013-06-12 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 組換えインターフェロンα２（ＩＦＮα２）変異体
CA2693326A1 (en) 2006-08-02 2008-02-07 Mcgill University Gm-csf and il-15 fusokines and methods for modulation of the immune response
US11535673B2 (en) 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
DK2160401T3 (da) * 2007-05-11 2014-10-20 Altor Bioscience Corp Fusionsmolekyler og il-15-varianter
EP2173377B1 (en) 2007-06-26 2017-11-29 University of Miami Antibody-endostatin fusion protein and its variants
CN101868246A (zh) 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
WO2010030671A1 (en) * 2008-09-09 2010-03-18 University Of Medicine And Dentistry Of New Jersey Type i interferon antagonists
WO2010036918A2 (en) 2008-09-26 2010-04-01 University Of Massachusetts Intracellular dna receptor
CA2749558C (en) 2008-12-08 2019-01-15 Complix Nv Single-chain antiparallel coiled coil proteins
PE20120630A1 (es) 2009-08-17 2012-05-26 Roche Glycart Ag Inmunoconjugados dirigidos
JP2013504539A (ja) 2009-09-10 2013-02-07 サイトス バイオテクノロジー アーゲー 糖尿病治療におけるインターロイキン１βムテイン・コンジュゲートの使用
EP2718457A4 (en) 2011-06-06 2014-12-24 Immungene Inc GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT
WO2013059885A2 (en) * 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Polypeptide constructs and uses thereof
AU2013211059B8 (en) * 2012-01-20 2017-12-21 Centre Hospitalier Regional Universitaire De Montpellier Targeted mutant alpha-helical bundle cytokines
CA2866126A1 (en) 2012-03-03 2013-09-12 Immungene, Inc. Engineered antibody-interferon mutant fusion molecules
US9732135B2 (en) * 2013-07-19 2017-08-15 Vib Vzw Targeting of human interferon antagonists

Also Published As

Publication number Publication date
CA2918119C (en) 2022-11-29
SG10202010429YA (en) 2020-11-27
AU2014292355A1 (en) 2016-02-04
SG11201600165WA (en) 2016-02-26
US20180057555A1 (en) 2018-03-01
WO2015007520A1 (en) 2015-01-22
KR20160108292A (ko) 2016-09-19
JP2016529232A (ja) 2016-09-23
US10072059B2 (en) 2018-09-11
US20180334488A1 (en) 2018-11-22
AU2014292355B2 (en) 2019-08-01
US20180334489A1 (en) 2018-11-22
US9732135B2 (en) 2017-08-15
MX375426B (es) 2025-03-06
US20210238247A1 (en) 2021-08-05
CA2918119A1 (en) 2015-01-22
EP3022230A1 (en) 2016-05-25
US20160159875A1 (en) 2016-06-09
EP3022230B1 (en) 2019-11-06
KR102305608B1 (ko) 2021-09-28
IL243459A0 (en) 2016-03-31
IL243459B (en) 2019-10-31
MX2016000721A (es) 2016-09-07
CN105658669A (zh) 2016-06-08
US10947288B2 (en) 2021-03-16

Similar Documents

Publication Publication Date Title
US10947288B2 (en) Targeting of human interferon antagonists
Larochette et al. IL-26, a cytokine with roles in extracellular DNA-induced inflammation and microbial defense
US20240309083A1 (en) Albumin binding domain fusion proteins
Adams et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F
Gao et al. Role of chemokine (C–X–C motif) ligand 10 (CXCL10) in renal diseases
AU2019201007B2 (en) Novel specific-binding polypeptides and uses thereof
Caramori et al. Cytokine inhibition in the treatment of COPD
Hernandez‐Santana et al. Current perspectives on the interleukin‐1 family as targets for inflammatory disease
Pan et al. Mutation of the IFNAR-1 receptor binding site of human IFN-α2 generates type I IFN competitive antagonists
US20090311802A1 (en) Isolated Soluble IL-TIF/IL-22 Receptor or Binding Protein Which Binds to IL-TIF/IL-22 and Uses Thereof
AU2005215771A1 (en) Agonists and antagonists of p28 EBI3 and WSX/TCCR for treating immune disorders
CA2903359A1 (en) Targeted modulation of macrophages
Martinez-Martinez et al. A novel gain-of-function STAT1 mutation resulting in basal phosphorylation of STAT1 and increased distal IFN-γ-mediated responses in chronic mucocutaneous candidiasis
KR102321861B1 (ko) Il-17a 및 il-17f 모두에 대한 단일클론 항체 및 이의 용도
Kim et al. Proteinase 3-processed form of the recombinant IL-32 separate domain
Class et al. Patent application title: TARGETING OF CYTOKINE ANTAGONISTS
HK1225047A1 (en) Targeting of cytokine antagonists
HK1225047B (en) Targeting of Cytokine Antagonists
BR112016001122B1 (pt) Proteína de fusão compreendendo um antagonista de interferon e uma fração de direcionamento
HK1208819A1 (en) Anti-ccl2 antibodies for treatment of scleroderma
US20260132191A1 (en) Methods for modulating activity of il-18 for treatment of cd4+ t cell mediated autoimmunity and immunopathology
Skouris Investigating the action mechanisms of IL-12 and IL-23 in an experimental model of Crohn’s disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180904

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190201

R150 Certificate of patent or registration of utility model

Ref document number: 6475712

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250